



July 30, 2010

Company name: Dainippon Sumitomo Pharma Co., Ltd.  
 Representative: Masayo Tada, President  
 (Securities Code: 4506, 1<sup>st</sup> Section of TSE and OSE)  
 Contact: Atsuko Higuchi, Corporate Communications  
 (Phone: +81-6-6203-1407)

## Revision of Financial Forecasts for the Fiscal Year Ending March 31, 2011

Dainippon Sumitomo Pharma Co., Ltd. announces the revision of its financial forecasts for the fiscal year ending March 31, 2011, which reflects changes in the Company's business performance since the previous forecasts announced on May 10, 2010.

(millions of yen)

### 1. Revision of cumulative consolidated financial forecasts for the second quarter of the fiscal year ending March 31, 2011 (April 1, 2010 – September 30, 2010)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share (yen)
Previous forecasts (A)	181,500	3,500	2,000	700	¥1.76
New forecasts (B)	186,000	14,500	13,500	8,100	¥20.39
(B) – (A)	4,500	11,000	11,500	7,400	
Change (%)	2.5	314.3	575.0	-	
(Reference) Cumulative results for the second quarter of the year ended March 31, 2010	132,210	18,919	19,053	12,654	¥31.85

### 2. Revision of consolidated financial forecasts for the fiscal year ending March 31, 2011 (April 1, 2010 – March 31, 2011)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share (yen)
Previous forecasts (A)	354,000	3,500	1,000	0	0
New forecasts (B)	359,000	8,500	6,000	3,000	¥7.55
(B) – (A)	5,000	5,000	5,000	3,000	
Change (%)	1.4	142.9	500.0	-	
(Reference) Results for the year ended March 31, 2010	296,261	35,624	33,837	20,958	¥52.75

### 3. Reason for revision

#### (1) Cumulative consolidated financial forecasts for the second quarter

Owing to brisk demand for our products in Europe and sales increase of major products of our U.S. subsidiary, sales are expected to surpass the estimate announced previously. Ratio of gross profit to sales is also expected to increase as a result of sales increase and improvement in cost to sales ratio, while general administrative and selling expenses are estimated to be lower than previously announced because some of the selling expenses and R&D expenses are anticipated to be carried forward to the third quarter, resulting in a lower level than previously announced.

Consequently, in the revised cumulative consolidated financial forecasts for the second

quarter of the fiscal year ending March 31, 2011, the Company anticipates that sales increase 4.5 billion yen to 186.0 billion yen, operating income increases 11.0 billion yen to 14.5 billion yen, ordinary income increases 11.5 billion yen to 13.5 billion yen, and net income increases 7.4 billion yen to 8.1 billion yen, compared with the previous forecasts dated May 10, 2010.

(2) The full year

Sales after the third quarter inclusive are expected to proceed nearly in line with the previous forecasts, and the increments up to the second quarter are expected to contribute to the increase in sales on a full year basis compared with the previous forecasts. Yearly general administrative and selling expenses are estimated to be unchanged from the previous forecast though there is some variance in timing, a shift from the first half.

Accordingly, the Company anticipates in the revised forecast for the fiscal year ending March 31, 2011 that sales increase 5.0 billion yen to 359.0 billion yen, operating income increases 5.0 billion yen to 8.5 billion yen, ordinary income increases 5.0 billion yen to 6.0 billion yen, and net income increases 3.0 billion yen to 3.0 billion yen, compared with the previous forecasts dated May 10, 2010.

Note: Forecasts shown above are based on management's assumptions and beliefs in light of the information currently available, and involve risks and uncertainties. Actual results may differ materially depending on a number of factors, including economic conditions.